NEW YORK, Oct 2 (Reuters) - SciClone Pharmaceuticals Inc (SCLN.O) dropped 18.1 percent in extended trade on Friday after the company said it discontinued the development of its experimental cancer drug following the recommendation by a data safety monitoring committee. [ID:nBNG485749]
(Reporting by Chuck Mikolajczak)
NEW YORK (Reuters) - In the nights before Christmas, some U.S. retailers are opening their doors round the clock to wring out every last possible holiday sale. | Video
The bubble has burst and the economy is bottoming out. So why are Americans still hesitant to buy new homes? Full Article
Ever the contrarian, fund manager Maura Shaughnessy finds ways to make money amid the market meltdown -- even if it means kicking executives in the shin. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
